The purpose of the study is to determine the pharmacoeconomic assessment of the technology for treating occupational diseases of coal workers associated with occupational dyskinesias in a hospital setting through the effective use of the resources of a medical organization. Materials and methods. The study of the pharmacoeconomic assessment of the technology for treating occupational diseases of workers in the coal industry associated with occupational dyskinesias was carried out on the basis of organizations providing medical care for workers in the coal industry. The pharmacoeconomic assessment of the technology for treating occupational diseases of workers in the coal industry associated with occupational dyskinesias was considered as the phenomenon under study. The source of information was the medical history of this diagnosis, which were treated at the Center for Miners' Medicine in 2014-2018. Results. The essence of the pharmacoeconomic analysis of treatment technologies lies in the total accounting of all costs of treating patients with a given disease in a hospital setting. The main costs include the cost of diagnostic, treatment and rehabilitation measures in a specialized hospital. The cost of diagnostics is calculated as the sum of prices for individual medical services in the form of clinical tests, X-ray diagnostics, ultrasound examination, etc. As a rule, their cost is calculated in the economic service of medical organizations, so you can use ready-made results. Conclusion. The calculations of the cost of treating patients according to the proposed scheme in the conditions of the occupational pathological department of the hospital allowed us to establish: the average level of costs for drug therapy, which states the average value of the actual costs of therapy for workers in the coal industry with occupational dyskinesias. Determination of the cost of the above basic costs for the projected number of patients makes it possible to form the base amount of funds required for the treatment of patients with a specific disease, including the cost of diagnostics and the cost of drug therapy.